Exact Sciences Shares Drop as Institutional Selling Counters Optimistic Trades; Ranks 460th in Trading Volume While Facing Analyst Downgrades and Rumors of a $21B Acquisition

Market Overview

On March 10, 2026, Exact Sciences (NASDAQ: EXAS) ended the trading session down 0.33%, with a trading volume of $270 million, ranking 460th among the most actively traded stocks that day. The share price opened at $103.71, just above its 50-day moving average of $102.69 and well above the 200-day average of $82.52. Despite the slight decline, the stock is trading close to its 52-week peak of $103.75, continuing a strong upward trend since hitting a low of $38.81 over the past year. The company currently holds a market cap of $19.8 billion, with a forward price-to-earnings ratio of -94.28 and a beta of 1.41, reflecting significant volatility compared to the broader market.

Main Influences

Recent movements in EXAS shares have been shaped by shifts in institutional ownership, changes in analyst recommendations, and the company’s financial performance. Notably, Blair William & Co. IL reduced its stake in EXAS by 14.9% during the third quarter, selling 24,493 shares and retaining 139,494 shares valued at $7.63 million. In contrast, other major investors such as OFI Invest Asset Management and China Universal Asset Management increased their holdings by 241.2% and 463.0%, respectively, highlighting differing perspectives on the company’s short-term outlook.

Analyst ratings have added to the uncertainty. TD Cowen downgraded EXAS from “Buy” to “Hold,” and William Blair shifted its rating from “Outperform” to “Market Perform.” Mizuho and Evercore maintained neutral stances, with price targets centered around $105. MarketBeat’s consensus rating of “Reduce” points to cautious optimism, while analysts anticipate a fiscal year loss per share of -$0.58, indicating ongoing profitability challenges.

In its fourth-quarter 2025 earnings report, Exact Sciences reported a loss of $0.21 per share—$0.29 worse than expected—despite a 23.1% increase in revenue compared to the previous year. The company’s net margin stood at -6.40%, and return on equity was 0.53%, suggesting operational inefficiencies. Nevertheless, the robust revenue growth demonstrates strong demand for its flagship Cologuard test and a growing diagnostics portfolio.

Technical analysis also influenced trading sentiment. The relative strength index (RSI) at 45.82 signaled a neutral stance, while the MACD (0.37) trailing its signal line (0.47) suggested potential short-term weakness. The absence of dividends and a payout ratio of 0.00% indicate the company’s commitment to reinvesting in growth rather than returning capital to shareholders.

There has also been speculation about a possible $21 billion acquisition bid from Abbott. If confirmed, such a deal could significantly impact the company’s valuation. However, no official statements have been made, leaving the stock’s future direction dependent on regulatory decisions and strategic developments.

Strategic Perspective

Exact Sciences’ primary business centers on its Cologuard test, a leading noninvasive screening tool for colorectal cancer. Collaborations with organizations like the Mayo Clinic and ongoing development of multi-cancer detection tests position the company to capitalize on the $100 billion global diagnostics market. However, high valuation ratios—such as a P/E/G of 2.36 and a debt-to-equity ratio of 0.97—reflect investor expectations for rapid revenue expansion to support current share prices.

The combination of mixed institutional activity and varied analyst opinions highlights uncertainty about the company’s ability to achieve sustainable profitability while scaling up operations. While increased investments from OFI and China Universal point to confidence in the company’s innovation pipeline, the reduction by Blair William & Co. and analyst downgrades suggest concerns about near-term execution risks.

In summary, Exact Sciences remains a high-volatility stock, driven by its leadership in cancer diagnostics and ongoing strategic initiatives. Investors should weigh the company’s strong revenue growth and expanding product offerings against persistent earnings pressures and cautious analyst sentiment. Potential mergers or regulatory breakthroughs could serve as catalysts, but the stock’s future will depend on how these competing factors play out.